SCHEMBL25923116

SCHEMBL25923116

Cc1cc(NC(=O)OC(C)(C)C)cc(C(=O)O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TPMT P51580 1/20 0.48
MEN1 O00255 6/20 0.47
KMT2A Q03164 6/20 0.47
POLB P06746 1/20 0.47
HCAR1 Q9BXC0 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA9 Q16790 1/20 0.42
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
MAPT P10636 1/20 0.40
USP2 O75604 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
P2RY14 Q15391 2/20 0.40
LCK P06239 1/20 0.40
FABP1 P07148 1/20 0.40
CYP17A1 P05093 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6232755 0.90 MEN1 (0.49) MEN1KMT2APOLBCA12CA1
SCHEMBL2890076 0.90 PKM (0.47) MEN1KMT2APOLBCA12CA1
SCHEMBL26162759 0.88 CYP17A1 (0.42) MEN1KMT2ACA12CA1CA9
SCHEMBL7477384 0.87 CA12 (0.48) MEN1KMT2ACA12CA1CA9
SCHEMBL31568470 0.86 KDM4E (0.55) MEN1KMT2ACA12CA1CA9
SCHEMBL22469882 0.86 KDM4E (0.55) MEN1KMT2ACA12CA1CA9
SCHEMBL2178704 0.84 CA12 (0.46) MEN1KMT2APOLBHCAR1CA12
SCHEMBL9396335 0.83 KDM4E (0.55) MEN1KMT2APOLBMAPTL3MBTL1
SCHEMBL29032844 0.83 L3MBTL1 (0.46) MEN1KMT2AHCAR1CA12CA1
SCHEMBL4726163 0.83 EPHX2 (0.42) MEN1KMT2APOLBCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230241257-A1 BIOTIN-MODIFIED DIMER AND USE THEREOF THE UNIVERSITY OF TOKYO (JP) 2023-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230241257-A1 BIOTIN-MODIFIED DIMER AND USE THEREOF BTD, HLCS, BRD4 TPMT 1559/4885MEN1 1671/4885KMT2A 2351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.